We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Silence Therapeutics plc (NASDAQ:SLN) ...
Silence Therapeutics plc (NASDAQ:SLN) missed earnings with its latest quarterly results, disappointing overly-optimistic forecasters. Statutory earnings fell substantially short of expectations, with ...
SLN is trading near the bottom of its 52-week range and above its 200-day simple moving average. Price change The price of SLN shares has increased $0.46 since the market last closed. This is a 9.10% ...
Shares of Silence Therapeutics SLN plunged 36.8% on Tuesday despite reporting positive end-of-treatment data from a mid-stage study of lead candidate, zerlasiran, to treat atherosclerotic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback